N/A
Completed N=22
Treatment With Namenda in Women at Risk for Cognitive Decline
Source: ClinicalTrials.gov NCT00242632 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2 — 20.41 percentage of target words recalled
Summary
This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2 |
20.41 | — |
| SECONDARY Change in Delis-Kaplan Executive Function System (DKEFS) Verbal Fluency Category Switching Between Time 1 and Time 2 |
1.11 | — |
Eligibility Criteria
Inclusion Criteria::
- Women between the ages of 50-65
- Willing to sign Human Subjects Protection Consent Form
- Personal or family history of mood disorder
- Hypothyroidism
- Diabetes
- Family history of Alzheimer's disease Exclusion Criteria:- Possible or probable Alzheimer's disease or dementia
- History of cerebrovascular disease
- History of myocardial infarction within the previous year
- History of unstable heart disease
- Uncontrolled hypertension
- Less than 8 years of education
- English as a 2nd language
- Uncorrected vision or hearing deficits
Data sourced from ClinicalTrials.gov (NCT00242632). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.